Working... Menu

Multicenter Trial of Immunologic Markers to Predict Long Term Virologic Outcomes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00440206
Recruitment Status : Completed
First Posted : February 26, 2007
Last Update Posted : February 27, 2007
Ontario HIV Treatment Network
Information provided by:
Ottawa Hospital Research Institute

Brief Summary:
Purpose is to identify whether immune markerscan predict success of salvage anti-retroviral therapy.

Condition or disease
HIV Infections

Detailed Description:
Over the last several years two markers of disease have been utilized to determine if antiretroviral therapy has been successful, one is a CD4 cell count (reflects the immunocompetence of an infected individual) and a HIV viral load (a blood test used to determine the amount of HIV in the infected individual). However in patients who fail their first line of therapythe likelihood of extended resuppressing viral replication with subsequent therapies may be as low as 25-50%. This information may take several months to determine the new therapies possible continuing success. It would be preferable to have additional markers that respond to therapies in the first several weeks to such therapies, therfore possibly offering patients alternate treatment earlier without potentiatinglong term side effects and possible further drug resistance.

Layout table for study information
Study Type : Observational
Enrollment : 50 participants
Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Multicenter Trial of Immunologic Markers to Predict Long Term Virologic Outcomes
Study Start Date : September 2001
Study Completion Date : December 2001

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient must be HIV infected
  • must be ≥18 years old
  • must have been taking the same combination ARV regimen (≥3 drugs) for at least 3 months.
  • Must be experiencing virologic failure (viral load ≥50 copies/mL on two occasions at least 2 weeks apart).
  • must be changed to a salvage antiretroviral regimen
  • Patient has to have signed and dated a full infomred consent.

Exclusion Criteria:

  • Patient with any of the following abnormal laboratory test results in the previous 3 months:
  • Hemaglobin <100 g/L
  • Platelet count <20,000 cells/L
  • INR ≥3.5 IU
  • PTT ≥60 IU
  • Patient with other significant underlying disease (non-HIV) that might impact immune markers ( eg. advanced liver disease, malignancy).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00440206

Layout table for location information
Canada, Ontario
McMaster Health Science Center
Hamilton, Ontario, Canada, L8N 3Z5
The Ottawa Hospital
Ottawa, Ontario, Canada, K1H 8L6
Maple Leaf Clinic
Toronto, Ontario, Canada, M5B 1L6
Toronto, Ontario, Canada, M5R 2M8
Windsor Regional Hospital
Windsor, Ontario, Canada, N8W 1L9
Sponsors and Collaborators
Ottawa Hospital Research Institute
Ontario HIV Treatment Network
Layout table for investigator information
Principal Investigator: J Angel, MD Ottawa Hospital Research Institute

Layout table for additonal information Identifier: NCT00440206     History of Changes
Other Study ID Numbers: 2002060-01H
First Posted: February 26, 2007    Key Record Dates
Last Update Posted: February 27, 2007
Last Verified: February 2007

Keywords provided by Ottawa Hospital Research Institute:
Immune Markers

Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases